PofoliaShared via Pofolia

BMJ· 2012Q1· Review

Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis

Katharine Ker, Phil Edwards, Pablo Perel, H. Shakur et al.

Short summary

Tranexamic acid reduces the need for blood transfusions in surgery by a third (RR 0.62, P<0.001), with reliable evidence available for over 10 years, according to a meta-analysis of 129 trials (10,488 patients).

AI-generated from the title and abstract; the full text is not read.

Key points

  • Tranexamic acid reduces blood transfusion needs in surgery by 38% (RR 0.62, P<0.001).
  • Reliable evidence for tranexamic acid's transfusion-reducing effect has existed for over 10 years.
  • The drug's effect on myocardial infarction, stroke, deep vein thrombosis, and pulmonary embolism is uncertain.
  • The impact of tranexamic acid on mortality is uncertain, particularly in trials with adequate concealment.

AI-generated from the title and abstract; the full text is not read.

Abstract

OBJECTIVE: To assess the effect of tranexamic acid on blood transfusion, thromboembolic events, and mortality in surgical patients. DESIGN: Systematic review and meta-analysis. DATA SOURCES: Cochrane central register of controlled trials, Medline, and Embase, from inception to September 2011, the World Health Organization International Clinical Trials Registry Platform, and the reference lists of relevant articles. STUDY SELECTION: Randomised controlled trials comparing tranexamic acid with no tranexamic acid or placebo in surgical patients. Outcome measures of interest were the number of patients receiving a blood transfusion; the number of patients with a thromboembolic event (myocardial infarction, stroke, deep vein thrombosis, and pulmonary embolism); and the number of deaths. Trials were included irrespective of language or publication status. RESULTS: 129 trials, totalling 10,488 patients, carried out between 1972 and 2011 were included. Tranexamic acid reduced the probability of receiving a blood transfusion by a third (risk ratio 0.62, 95% confidence interval 0.58 to 0.65; P<0.001). This effect remained when the analysis was restricted to trials using adequate allocation concealment (0.68, 0.62 to 0.74; P<0.001). The effect of tranexamic acid on myocardial infarction (0.68, 0.43 to 1.09; P = 0.11), stroke (1.14, 0.65 to 2.00; P = 0.65), deep vein thrombosis (0.86, 0.53 to 1.39; P = 0.54), and pulmonary embolism (0.61, 0.25 to 1.47; P=0.27) was uncertain. Fewer deaths occurred in the tranexamic acid group (0.61, 0.38 to 0.98; P = 0.04), although when the analysis was restricted to trials using adequate concealment there was considerable uncertainty (0.67, 0.33 to 1.34; P = 0.25). Cumulative meta-analysis showed that reliable evidence that tranexamic acid reduces the need for transfusion has been available for over 10 years. CONCLUSIONS: Strong evidence that tranexamic acid reduces blood transfusion in surgery has been available for many years. Further trials on the effect of tranexamic acid on blood transfusion are unlikely to add useful new information. However, the effect of tranexamic acid on thromboembolic events and mortality remains uncertain. Surgical patients should be made aware of this evidence so that they can make an informed choice.

The authors' abstract, as published at the source. BMJ, 2012 · DOI ↗

TakeawaysPremium
Ask the paperFree account

Continue with a free account

Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.

Continue free on the web

Sign in with Google or Apple; no card needed. You come back to this paper.

On your phone:

Field: Biochemistry (Medicine)

BiochemistryMedicine